DE69232709D1 - Zusammensetzungen zur Erhöhung des Bildkontrastes bei Untersuchungen des Verdauungstraktes von Patienten - Google Patents

Zusammensetzungen zur Erhöhung des Bildkontrastes bei Untersuchungen des Verdauungstraktes von Patienten

Info

Publication number
DE69232709D1
DE69232709D1 DE69232709T DE69232709T DE69232709D1 DE 69232709 D1 DE69232709 D1 DE 69232709D1 DE 69232709 T DE69232709 T DE 69232709T DE 69232709 T DE69232709 T DE 69232709T DE 69232709 D1 DE69232709 D1 DE 69232709D1
Authority
DE
Germany
Prior art keywords
compositions
digestive tract
examinations
patients
image contrast
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69232709T
Other languages
English (en)
Other versions
DE69232709T2 (de
Inventor
Herve Tournier
Roland Hyacinthe
Friedrich Cavagna
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bracco International BV
Original Assignee
Bracco International BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bracco International BV filed Critical Bracco International BV
Application granted granted Critical
Publication of DE69232709D1 publication Critical patent/DE69232709D1/de
Publication of DE69232709T2 publication Critical patent/DE69232709T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
    • G01R33/00—Arrangements or instruments for measuring magnetic variables
    • G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
    • G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
    • G01R33/48—NMR imaging systems
    • G01R33/54—Signal processing systems, e.g. using pulse sequences ; Generation or control of pulse sequences; Operator console
    • G01R33/56—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution
    • G01R33/5601—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution involving use of a contrast agent for contrast manipulation, e.g. a paramagnetic, super-paramagnetic, ferromagnetic or hyperpolarised contrast agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1833—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with a small organic molecule
    • A61K49/1845—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with a small organic molecule the small organic molecule being a carbohydrate (monosaccharides, discacharides)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
    • A61K49/1854—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly(meth)acrylate, polyacrylamide, polyvinylpyrrolidone, polyvinylalcohol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
    • A61K49/1863—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being a polysaccharide or derivative thereof, e.g. chitosan, chitin, cellulose, pectin, starch
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/189—Host-guest complexes, e.g. cyclodextrins
    • A61K49/1893—Molecular sieves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
    • A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
    • A61K49/223—Microbubbles, hollow microspheres, free gas bubbles, gas microspheres
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
    • A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
    • A61K49/226—Solutes, emulsions, suspensions, dispersions, semi-solid forms, e.g. hydrogels
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/24—Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry
DE69232709T 1991-02-15 1992-02-05 Zusammensetzungen zur Erhöhung des Bildkontrastes bei Untersuchungen des Verdauungstraktes von Patienten Expired - Lifetime DE69232709T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP91810105 1991-02-15

Publications (2)

Publication Number Publication Date
DE69232709D1 true DE69232709D1 (de) 2002-09-05
DE69232709T2 DE69232709T2 (de) 2003-04-10

Family

ID=8208821

Family Applications (3)

Application Number Title Priority Date Filing Date
DE69229358T Expired - Lifetime DE69229358T2 (de) 1991-02-15 1992-02-05 Zusammensetzungen zur Erhöhung des Bildkontrasts in der Diagnostik des Gastrointestinaltrakts
DE69203004T Expired - Lifetime DE69203004T2 (de) 1991-02-15 1992-02-05 Zusammensetzung zur Erhöhung des Bildkontrastes bei Bilderzeugung vom Verdauungstrakt von Patienten.
DE69232709T Expired - Lifetime DE69232709T2 (de) 1991-02-15 1992-02-05 Zusammensetzungen zur Erhöhung des Bildkontrastes bei Untersuchungen des Verdauungstraktes von Patienten

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DE69229358T Expired - Lifetime DE69229358T2 (de) 1991-02-15 1992-02-05 Zusammensetzungen zur Erhöhung des Bildkontrasts in der Diagnostik des Gastrointestinaltrakts
DE69203004T Expired - Lifetime DE69203004T2 (de) 1991-02-15 1992-02-05 Zusammensetzung zur Erhöhung des Bildkontrastes bei Bilderzeugung vom Verdauungstrakt von Patienten.

Country Status (8)

Country Link
US (4) US5370901A (de)
EP (3) EP0502814B1 (de)
JP (1) JPH05148161A (de)
AT (3) ATE180678T1 (de)
DE (3) DE69229358T2 (de)
DK (1) DK0502814T3 (de)
ES (1) ES2074350T3 (de)
GR (1) GR3017002T3 (de)

Families Citing this family (170)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5562099A (en) * 1990-10-05 1996-10-08 Massachusetts Institute Of Technology Polymeric microparticles containing agents for imaging
US5370901A (en) * 1991-02-15 1994-12-06 Bracco International B.V. Compositions for increasing the image contrast in diagnostic investigations of the digestive tract of patients
GB9106686D0 (en) * 1991-03-28 1991-05-15 Hafslund Nycomed As Improvements in or relating to contrast agents
WO1992021382A1 (en) * 1991-06-03 1992-12-10 Holmes, Michael, John Improvements in or relating to contrast agents
DE69230885T3 (de) * 1991-09-17 2008-01-24 Ge Healthcare As Gasförmige ultraschallkontrastmittel
MX9205298A (es) * 1991-09-17 1993-05-01 Steven Carl Quay Medios gaseosos de contraste de ultrasonido y metodo para seleccionar gases para usarse como medios de contraste de ultrasonido
US5409688A (en) * 1991-09-17 1995-04-25 Sonus Pharmaceuticals, Inc. Gaseous ultrasound contrast media
US6723303B1 (en) 1991-09-17 2004-04-20 Amersham Health, As Ultrasound contrast agents including protein stabilized microspheres of perfluoropropane, perfluorobutane or perfluoropentane
GB9200388D0 (en) * 1992-01-09 1992-02-26 Nycomed As Improvements in or relating to contrast agents
DE69207589T2 (de) * 1992-06-01 1996-05-23 Basf Ag Anwendung von Dispersionen von magneto-ionischen Partikeln in MRI-Kontrast-Mitteln
IL108416A (en) 1993-01-25 1998-10-30 Sonus Pharma Inc Colloids with phase difference as contrast ultrasound agents
CN1068230C (zh) * 1993-01-25 2001-07-11 索纳斯药品有限公司 用作超声造影剂的相转变胶体
US5558855A (en) * 1993-01-25 1996-09-24 Sonus Pharmaceuticals Phase shift colloids as ultrasound contrast agents
US5439686A (en) * 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
FR2703250A1 (fr) * 1993-03-30 1994-10-07 Chicouri Marcel Nouvelles compositions pharmaceutiques à base de bismuth et leur procédé de préparation.
EP0741581A1 (de) * 1994-01-28 1996-11-13 Nycomed Imaging As Orales magnetischen teilchenpräparat
US6405732B1 (en) 1994-06-24 2002-06-18 Curon Medical, Inc. Method to treat gastric reflux via the detection and ablation of gastro-esophageal nerves and receptors
US6044846A (en) 1994-06-24 2000-04-04 Edwards; Stuart D. Method to treat esophageal sphincters
US6092528A (en) 1994-06-24 2000-07-25 Edwards; Stuart D. Method to treat esophageal sphincters
US6733495B1 (en) 1999-09-08 2004-05-11 Curon Medical, Inc. Systems and methods for monitoring and controlling use of medical devices
US6056744A (en) 1994-06-24 2000-05-02 Conway Stuart Medical, Inc. Sphincter treatment apparatus
US6009877A (en) 1994-06-24 2000-01-04 Edwards; Stuart D. Method for treating a sphincter
DE4424233C1 (de) * 1994-07-09 1995-12-07 Thomas Gieselmann Orales Echokontrastmittel für Ultraschalldiagnostik
DE4428851C2 (de) * 1994-08-04 2000-05-04 Diagnostikforschung Inst Eisen enthaltende Nanopartikel, ihre Herstellung und Anwendung in der Diagnostik und Therapie
DE4428589C2 (de) * 1994-08-12 1996-11-07 Byk Gulden Lomberg Chem Fab Orales Echokontrastmittel
US6992107B1 (en) * 1995-03-10 2006-01-31 Photocure Asa Esters of 5-aminolevulinic acid and their use as photosensitizing compounds in photochemotherapy
US5804162A (en) * 1995-06-07 1998-09-08 Alliance Pharmaceutical Corp. Gas emulsions stabilized with fluorinated ethers having low Ostwald coefficients
ES2112765B1 (es) * 1995-08-02 1999-03-01 Cantabria Ind Farmaceutica Sa Procedimiento para la obtencion de formulaciones de constraste radiologico, para exploraciones gastrointestinales de uso extemporaneo y directo.
WO1997016474A1 (en) * 1995-11-01 1997-05-09 Bracco Research S.A. Targeted magnetically labeled molecular marker systems for the nmr imaging
US5611344A (en) * 1996-03-05 1997-03-18 Acusphere, Inc. Microencapsulated fluorinated gases for use as imaging agents
JP3178724B2 (ja) * 1996-03-05 2001-06-25 エイカスフィアー・インコーポレーテッド 画像化剤として使用するためのミクロカプセル化フッ素化ガス
US8353908B2 (en) 1996-09-20 2013-01-15 Novasys Medical, Inc. Treatment of tissue in sphincters, sinuses, and orifices
US20070092563A1 (en) 1996-10-01 2007-04-26 Abraxis Bioscience, Inc. Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US6464697B1 (en) 1998-02-19 2002-10-15 Curon Medical, Inc. Stomach and adjoining tissue regions in the esophagus
US6106473A (en) 1996-11-06 2000-08-22 Sts Biopolymers, Inc. Echogenic coatings
US7229413B2 (en) * 1996-11-06 2007-06-12 Angiotech Biocoatings Corp. Echogenic coatings with overcoat
IL121312A (en) * 1997-07-14 2001-09-13 Technion Res & Dev Foundation Microelectronic components, their manufacture and electronic networks containing them
US9023031B2 (en) 1997-08-13 2015-05-05 Verathon Inc. Noninvasive devices, methods, and systems for modifying tissues
US7637948B2 (en) 1997-10-10 2009-12-29 Senorx, Inc. Tissue marking implant
US8668737B2 (en) 1997-10-10 2014-03-11 Senorx, Inc. Tissue marking implant
US6270464B1 (en) 1998-06-22 2001-08-07 Artemis Medical, Inc. Biopsy localization method and device
AU2114299A (en) 1998-01-14 1999-08-02 Conway-Stuart Medical, Inc. Electrosurgical device for sphincter treatment
US6440128B1 (en) 1998-01-14 2002-08-27 Curon Medical, Inc. Actively cooled electrode assemblies for forming lesions to treat dysfunction in sphincters and adjoining tissue regions
IT1298269B1 (it) * 1998-02-18 1999-12-20 Promefarm S R L Uso di un polietilenglicole come mezzo di contrasto in ecografia
US6258087B1 (en) 1998-02-19 2001-07-10 Curon Medical, Inc. Expandable electrode assemblies for forming lesions to treat dysfunction in sphincters and adjoining tissue regions
US8906010B2 (en) 1998-02-19 2014-12-09 Mederi Therapeutics, Inc. Graphical user interface for association with an electrode structure deployed in contact with a tissue region
AU752243B2 (en) 1998-02-19 2002-09-12 Curon Medical, Inc. Electrosurgical sphincter treatment apparatus
US6355031B1 (en) 1998-02-19 2002-03-12 Curon Medical, Inc. Control systems for multiple electrode arrays to create lesions in tissue regions at or near a sphincter
US6273886B1 (en) 1998-02-19 2001-08-14 Curon Medical, Inc. Integrated tissue heating and cooling apparatus
US6423058B1 (en) 1998-02-19 2002-07-23 Curon Medical, Inc. Assemblies to visualize and treat sphincters and adjoining tissue regions
CA2320105A1 (en) 1998-02-19 1999-08-26 Curon Medical, Inc. Apparatus to detect and electrosurgically treat aberrant myoelectric activity
US7165551B2 (en) 1998-02-19 2007-01-23 Curon Medical, Inc. Apparatus to detect and treat aberrant myoelectric activity
US6402744B2 (en) 1998-02-19 2002-06-11 Curon Medical, Inc. Systems and methods for forming composite lesions to treat dysfunction in sphincters and adjoining tissue regions
US6790207B2 (en) 1998-06-04 2004-09-14 Curon Medical, Inc. Systems and methods for applying a selected treatment agent into contact with tissue to treat disorders of the gastrointestinal tract
US6325798B1 (en) 1998-02-19 2001-12-04 Curon Medical, Inc. Vacuum-assisted systems and methods for treating sphincters and adjoining tissue regions
US6358245B1 (en) 1998-02-19 2002-03-19 Curon Medical, Inc. Graphical user interface for association with an electrode structure deployed in contact with a tissue region
US20030135206A1 (en) 1998-02-27 2003-07-17 Curon Medical, Inc. Method for treating a sphincter
AU754424B2 (en) 1998-02-27 2002-11-14 Curon Medical, Inc. Apparatus to electrosurgically treat esophageal sphincters
US6497706B1 (en) 1998-03-03 2002-12-24 Senorx, Inc. Biopsy device and method of use
US6758848B2 (en) 1998-03-03 2004-07-06 Senorx, Inc. Apparatus and method for accessing a body site
US6638234B2 (en) 1998-03-03 2003-10-28 Senorx, Inc. Sentinel node location and biopsy
AU753618B2 (en) 1998-03-06 2002-10-24 Curon Medical, Inc. Apparatus to electrosurgically treat esophageal sphincters
US6347241B2 (en) * 1999-02-02 2002-02-12 Senorx, Inc. Ultrasonic and x-ray detectable biopsy site marker and apparatus for applying it
US6161034A (en) * 1999-02-02 2000-12-12 Senorx, Inc. Methods and chemical preparations for time-limited marking of biopsy sites
US6540695B1 (en) 1998-04-08 2003-04-01 Senorx, Inc. Biopsy anchor device with cutter
WO1999055245A1 (en) 1998-04-30 1999-11-04 Edwards Stuart D Electrosurgical sphincter treatment apparatus
US6802841B2 (en) 1998-06-04 2004-10-12 Curon Medical, Inc. Systems and methods for applying a selected treatment agent into contact with tissue to treat sphincter dysfunction
US6679851B2 (en) 1998-09-01 2004-01-20 Senorx, Inc. Tissue accessing and anchoring device and method
US7651505B2 (en) 2002-06-17 2010-01-26 Senorx, Inc. Plugged tip delivery for marker placement
US7983734B2 (en) * 2003-05-23 2011-07-19 Senorx, Inc. Fibrous marker and intracorporeal delivery thereof
US8498693B2 (en) 1999-02-02 2013-07-30 Senorx, Inc. Intracorporeal marker and marker delivery device
US20090216118A1 (en) 2007-07-26 2009-08-27 Senorx, Inc. Polysaccharide markers
US6862470B2 (en) 1999-02-02 2005-03-01 Senorx, Inc. Cavity-filling biopsy site markers
US9820824B2 (en) 1999-02-02 2017-11-21 Senorx, Inc. Deployment of polysaccharide markers for treating a site within a patent
US6725083B1 (en) * 1999-02-02 2004-04-20 Senorx, Inc. Tissue site markers for in VIVO imaging
US8361082B2 (en) 1999-02-02 2013-01-29 Senorx, Inc. Marker delivery device with releasable plug
AU4696100A (en) 1999-05-04 2000-11-17 Curon Medical, Inc. Electrodes for creating lesions in tissue regions at or near a sphincter
US6575991B1 (en) 1999-06-17 2003-06-10 Inrad, Inc. Apparatus for the percutaneous marking of a lesion
GB9915398D0 (en) * 1999-07-02 1999-09-01 Baker Matthew J Magnetic particles
AU7480200A (en) 1999-09-08 2001-04-10 Curon Medical, Inc. System for controlling a family of treatment devices
CA2384273A1 (en) 1999-09-08 2001-03-15 Curon Medical, Inc. Systems and methods for monitoring and controlling use of medical devices
CA2825425C (en) 1999-11-16 2016-03-22 Covidien Lp System and method of treating abnormal tissue in the human esophagus
US20040215235A1 (en) 1999-11-16 2004-10-28 Barrx, Inc. Methods and systems for determining physiologic characteristics for treatment of the esophagus
US20060095032A1 (en) 1999-11-16 2006-05-04 Jerome Jackson Methods and systems for determining physiologic characteristics for treatment of the esophagus
US6547776B1 (en) 2000-01-03 2003-04-15 Curon Medical, Inc. Systems and methods for treating tissue in the crura
US8845632B2 (en) 2000-05-18 2014-09-30 Mederi Therapeutics, Inc. Graphical user interface for monitoring and controlling use of medical devices
GB0018527D0 (en) * 2000-07-27 2000-09-13 Photocure Asa Composition
US6911204B2 (en) * 2000-08-11 2005-06-28 Favrille, Inc. Method and composition for altering a B cell mediated pathology
KR20030064377A (ko) * 2000-08-11 2003-07-31 파브릴, 인크. Ｔ 세포 매개 병증을 개선시키기 위한 방법 및 조성물
US7306591B2 (en) 2000-10-02 2007-12-11 Novasys Medical, Inc. Apparatus and methods for treating female urinary incontinence
US6544185B2 (en) 2000-10-23 2003-04-08 Valentino Montegrande Ultrasound imaging marker and method of use
WO2002041786A2 (en) 2000-11-20 2002-05-30 Senorx, Inc. Tissue site markers for in vivo imaging
US7014610B2 (en) 2001-02-09 2006-03-21 Medtronic, Inc. Echogenic devices and methods of making and using such devices
US7288574B2 (en) * 2001-07-18 2007-10-30 Eckert C Edward Two-phase oxygenated solution and method of use
US20030083286A1 (en) * 2001-08-22 2003-05-01 Ching-Leou Teng Bioadhesive compositions and methods for enhanced intestinal drug absorption
US20030124196A1 (en) * 2001-08-22 2003-07-03 Susan Weinbach Pulsatile release compositions and methods for enhanced intestinal drug absorption
GB0120645D0 (en) 2001-08-24 2001-10-17 Smiths Group Plc Medico-surgical devices
US6654629B2 (en) 2002-01-23 2003-11-25 Valentino Montegrande Implantable biomarker and method of use
US20030185757A1 (en) * 2002-03-27 2003-10-02 Mayk Kresse Iron-containing nanoparticles with double coating and their use in diagnosis and therapy
US20060036158A1 (en) 2003-11-17 2006-02-16 Inrad, Inc. Self-contained, self-piercing, side-expelling marking apparatus
US20040175329A1 (en) * 2003-03-07 2004-09-09 Fisher John Steele Method for continuous visualization of a body lumen
GB0307350D0 (en) 2003-03-29 2003-05-07 Smiths Group Plc Catheters
EP1615557B1 (de) * 2003-04-15 2012-09-19 Philips Intellectual Property & Standards GmbH Verfahren und vorrichtung zur verbesserten ermittlung der räumlichen verteilung nicht agglomerierter magnetischer partikel in einem untersuchungsbereich
EP1615556B1 (de) * 2003-04-15 2012-06-13 Philips Intellectual Property & Standards GmbH Verfahren zur bestimmung von zustandsgrössen sowie von zustandsgrössenänderungen
US20060248944A1 (en) * 2003-04-15 2006-11-09 Koninklijke Philips Electronics N.V. Method to determine the spatial distribution of magnetic particles and magnetic particle administering compositions
US20050119562A1 (en) * 2003-05-23 2005-06-02 Senorx, Inc. Fibrous marker formed of synthetic polymer strands
US7877133B2 (en) 2003-05-23 2011-01-25 Senorx, Inc. Marker or filler forming fluid
EP1663281B1 (de) 2003-08-29 2013-12-25 Dyax Corp. Poly-pegylierte proteasehemmer
US20050273002A1 (en) 2004-06-04 2005-12-08 Goosen Ryan L Multi-mode imaging marker
US9408592B2 (en) 2003-12-23 2016-08-09 Senorx, Inc. Biopsy device with aperture orientation and improved tip
US7150745B2 (en) 2004-01-09 2006-12-19 Barrx Medical, Inc. Devices and methods for treatment of luminal tissue
US8012457B2 (en) 2004-06-04 2011-09-06 Acusphere, Inc. Ultrasound contrast agent dosage formulation
US20060140871A1 (en) * 2004-11-30 2006-06-29 Sillerud Laurel O Magnetic resonance imaging of prostate cancer
US8343071B2 (en) 2004-12-16 2013-01-01 Senorx, Inc. Biopsy device with aperture orientation and improved tip
US10357328B2 (en) 2005-04-20 2019-07-23 Bard Peripheral Vascular, Inc. and Bard Shannon Limited Marking device with retractable cannula
US9095325B2 (en) 2005-05-23 2015-08-04 Senorx, Inc. Tissue cutting member for a biopsy device
LT2460831T (lt) 2005-05-27 2016-12-12 Biogen Ma Inc. Tweak rišantys antikūnai
US20100055040A1 (en) * 2005-06-21 2010-03-04 Periasamy Muthunadar P Optical Imaging Contrast Agents
EP1738773A1 (de) * 2005-06-29 2007-01-03 Schering AG Magnetische Eisenoxidpartikel enthaltende Zusammensetzung und deren Vervendung in bildgebenden Verfahren
US8317725B2 (en) 2005-08-05 2012-11-27 Senorx, Inc. Biopsy device with fluid delivery to tissue specimens
US7572236B2 (en) 2005-08-05 2009-08-11 Senorx, Inc. Biopsy device with fluid delivery to tissue specimens
CA2562580C (en) 2005-10-07 2014-04-29 Inrad, Inc. Drug-eluting tissue marker
US7959627B2 (en) 2005-11-23 2011-06-14 Barrx Medical, Inc. Precision ablating device
US7997278B2 (en) 2005-11-23 2011-08-16 Barrx Medical, Inc. Precision ablating method
US8702694B2 (en) 2005-11-23 2014-04-22 Covidien Lp Auto-aligning ablating device and method of use
ES2443526T3 (es) 2006-10-23 2014-02-19 C.R. Bard, Inc. Marcador mamario
US9579077B2 (en) 2006-12-12 2017-02-28 C.R. Bard, Inc. Multiple imaging mode tissue marker
EP2101670B1 (de) 2006-12-18 2013-07-31 C.R.Bard, Inc. Biopsiemarker mit in situ erzeugten bildgebungseigenschaften
WO2008137757A1 (en) 2007-05-04 2008-11-13 Barrx Medical, Inc. Method and apparatus for gastrointestinal tract ablation for treatment of obesity
US8784338B2 (en) 2007-06-22 2014-07-22 Covidien Lp Electrical means to normalize ablational energy transmission to a luminal tissue surface of varying size
US8251992B2 (en) 2007-07-06 2012-08-28 Tyco Healthcare Group Lp Method and apparatus for gastrointestinal tract ablation to achieve loss of persistent and/or recurrent excess body weight following a weight-loss operation
KR101513926B1 (ko) 2007-07-06 2015-04-21 코비디엔 엘피 지혈을 해내고 출혈 경향을 갖는 환부를 근절하기 위한 위장관 내 절제
US8646460B2 (en) 2007-07-30 2014-02-11 Covidien Lp Cleaning device and methods
US8273012B2 (en) 2007-07-30 2012-09-25 Tyco Healthcare Group, Lp Cleaning device and methods
GB0716885D0 (en) 2007-08-30 2007-10-10 United Arab Emirates Universit Diagnostic agent
WO2009099767A2 (en) 2008-01-31 2009-08-13 C.R. Bard, Inc. Biopsy tissue marker
EP3348573B1 (de) 2008-04-25 2020-04-22 Dyax Corp. Methode zur herstellung von antikörper gegen fcrn
GB0811856D0 (en) * 2008-06-27 2008-07-30 Ucl Business Plc Magnetic microbubbles, methods of preparing them and their uses
US9327061B2 (en) 2008-09-23 2016-05-03 Senorx, Inc. Porous bioabsorbable implant
US9782565B2 (en) 2008-10-01 2017-10-10 Covidien Lp Endoscopic ultrasound-guided biliary access system
US11298113B2 (en) 2008-10-01 2022-04-12 Covidien Lp Device for needle biopsy with integrated needle protection
US9186128B2 (en) 2008-10-01 2015-11-17 Covidien Lp Needle biopsy device
US9332973B2 (en) 2008-10-01 2016-05-10 Covidien Lp Needle biopsy device with exchangeable needle and integrated needle protection
US8968210B2 (en) 2008-10-01 2015-03-03 Covidien LLP Device for needle biopsy with integrated needle protection
US20110190662A1 (en) * 2008-10-01 2011-08-04 Beacon Endoscopic Corporation Rapid exchange fna biopsy device with diagnostic and therapeutic capabilities
AU2009303453B2 (en) 2008-10-14 2015-02-26 Dyax Corp. Use of IGF-II/IGF-IIE binding for the treatment and prevention of systemic sclerosis associated pulmonary fibrosis
WO2010077244A1 (en) 2008-12-30 2010-07-08 C.R. Bard Inc. Marker delivery device for tissue marker placement
US9474565B2 (en) 2009-09-22 2016-10-25 Mederi Therapeutics, Inc. Systems and methods for treating tissue with radiofrequency energy
US9750563B2 (en) 2009-09-22 2017-09-05 Mederi Therapeutics, Inc. Systems and methods for treating tissue with radiofrequency energy
US20110112529A1 (en) 2009-09-22 2011-05-12 Mederi Therapeutics Inc. Systems and methods for controlling use and operation of a family of different treatment devices
US10386990B2 (en) 2009-09-22 2019-08-20 Mederi Rf, Llc Systems and methods for treating tissue with radiofrequency energy
US9775664B2 (en) 2009-09-22 2017-10-03 Mederi Therapeutics, Inc. Systems and methods for treating tissue with radiofrequency energy
HUE057244T2 (hu) 2010-01-06 2022-04-28 Takeda Pharmaceuticals Co Plazma kallikreint kötõ fehérjék
US10278774B2 (en) 2011-03-18 2019-05-07 Covidien Lp Selectively expandable operative element support structure and methods of use
US9359438B2 (en) 2011-06-02 2016-06-07 Dyax Corporation Human neonatal Fc receptor antibodies and methods of use thereof
BR112014014412A2 (pt) 2011-12-16 2017-06-13 Nanobiotix nanopartículas compreendendo materiais metálicos e de óxido de háfnio, sua preparação e uso
US8403927B1 (en) 2012-04-05 2013-03-26 William Bruce Shingleton Vasectomy devices and methods
US9902775B2 (en) 2012-12-10 2018-02-27 Biogen Ma Inc. Anti-blood dendritic cell antigen 2 antibodies and uses thereof
WO2014143739A2 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Anti-alpha v beta 6 antibodies and uses thereof
WO2014144466A1 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Anti-alpha v beta 6 antibodies and uses thereof
CN105431174B (zh) * 2013-06-20 2019-06-07 纳米生物技术公司 用于肿瘤学的组合物和方法
USD715942S1 (en) 2013-09-24 2014-10-21 C. R. Bard, Inc. Tissue marker for intracorporeal site identification
USD715442S1 (en) 2013-09-24 2014-10-14 C. R. Bard, Inc. Tissue marker for intracorporeal site identification
USD716450S1 (en) 2013-09-24 2014-10-28 C. R. Bard, Inc. Tissue marker for intracorporeal site identification
USD716451S1 (en) 2013-09-24 2014-10-28 C. R. Bard, Inc. Tissue marker for intracorporeal site identification
WO2015057939A1 (en) 2013-10-18 2015-04-23 Biogen Idec Ma Inc. Anti-s1p4 antibodies and uses thereof
AU2015243218B2 (en) * 2014-04-11 2019-03-21 Covidien Lp Tagged surgical instruments and methods therefor
US11096962B2 (en) 2015-05-28 2021-08-24 Nanobiotix Nanoparticles for use as a therapeutic vaccine
CN109261342B (zh) * 2018-08-02 2020-08-07 河南省核力科技发展有限公司 一种基于辐照接枝的选煤用重介质的制备方法
US20210299284A1 (en) * 2018-08-09 2021-09-30 The Regents Of The University Of California Method and material to acquire magnetic resonance imaging data

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4335094A (en) * 1979-01-26 1982-06-15 Mosbach Klaus H Magnetic polymer particles
EP0113367B1 (de) 1982-07-14 1989-02-15 Battelle Development Corporation Verfahren zur herstellung von überzügen auf substraten aus vernetzbaren harzen
US5141738A (en) * 1983-04-15 1992-08-25 Schering Aktiengesellschaft Ultrasonic contrast medium comprising gas bubbles and solid lipophilic surfactant-containing microparticles and use thereof
US4554088A (en) * 1983-05-12 1985-11-19 Advanced Magnetics Inc. Magnetic particles for use in separations
GB8408127D0 (en) * 1984-03-29 1984-05-10 Nyegaard & Co As Contrast agents
DE3577185D1 (de) * 1984-11-01 1990-05-23 Nycomed As Paramagnetische kontrastmittel fuer die anwendung in "in vivo" nmr-diagnostischen methoden und die herstellung davon.
US4795698A (en) * 1985-10-04 1989-01-03 Immunicon Corporation Magnetic-polymer particles
IT1213029B (it) * 1986-01-30 1989-12-07 Bracco Ind Chimica Spa Chelati di ioni metallici paramagnetici.
US4871716A (en) * 1986-02-04 1989-10-03 University Of Florida Magnetically responsive, hydrophilic microspheres for incorporation of therapeutic substances and methods of preparation thereof
US4729892A (en) * 1986-03-21 1988-03-08 Ciba-Geigy Corporation Use of cross-linked hydrogel materials as image contrast agents in proton nuclear magnetic resonance tomography and tissue phantom kits containing such materials
US5262176A (en) * 1986-07-03 1993-11-16 Advanced Magnetics, Inc. Synthesis of polysaccharide covered superparamagnetic oxide colloids
US4827945A (en) * 1986-07-03 1989-05-09 Advanced Magnetics, Incorporated Biologically degradable superparamagnetic materials for use in clinical applications
US4770183A (en) * 1986-07-03 1988-09-13 Advanced Magnetics Incorporated Biologically degradable superparamagnetic particles for use as nuclear magnetic resonance imaging agents
US4863717A (en) * 1986-11-10 1989-09-05 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of The University Of Oregon Methods for circumventing the problem of free radial reduction associated with the use of stable nitroxide free radicals as contrast agents for magnetic reasonance imaging
GB8701054D0 (en) * 1987-01-16 1987-02-18 Amersham Int Plc Contrast agent for nmr scanning
US4822594A (en) * 1987-01-27 1989-04-18 Gibby Wendell A Contrast enhancing agents for magnetic resonance images
DE3709851A1 (de) * 1987-03-24 1988-10-06 Silica Gel Gmbh Adsorptions Te Nmr-diagnostische fluessigkeitszusammensetzungen
DE3724188C2 (de) * 1987-07-17 1995-05-18 Heinz Dr Gries Metallhaltige Oligosaccharid-Polysulfate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Mittel
CH672922A5 (de) 1987-09-25 1990-01-15 Battelle Memorial Institute
US4927624A (en) * 1987-11-19 1990-05-22 The University Of Rochester Clay magnetic resonance contrast agents for gastrointestinal comsumption or introduction
IE61591B1 (en) 1987-12-29 1994-11-16 Molecular Biosystems Inc Concentrated stabilized microbubble-type ultrasonic imaging agent and method of production
GB8801646D0 (en) * 1988-01-26 1988-02-24 Nycomed As Chemical compounds
KR0133132B1 (ko) 1988-02-05 1998-04-17 쉐링 아게, 베를린 운트 베르크카멘 초음파 조영제, 이의 제법 및 이의 진단제로서의 용도
US5023072A (en) * 1988-08-10 1991-06-11 University Of New Mexico Paramagnetic/superparamagnetic/ferromagnetic sucrose sulfate compositions for magnetic resonance imaging of the gastrointestinal tract
US5260050A (en) * 1988-09-29 1993-11-09 Ranney David F Methods and compositions for magnetic resonance imaging comprising superparamagnetic ferromagnetically coupled chromium complexes
WO1990007380A2 (en) * 1988-12-28 1990-07-12 Stefan Miltenyi Methods and materials for high gradient magnetic separation of biological materials
DE3908623A1 (de) * 1989-03-16 1990-09-20 Ulrich Dr Lang Verfahren zur sterischen stabilisierung von eisen-ferrit-partikeln
US5114703A (en) * 1989-05-30 1992-05-19 Alliance Pharmaceutical Corp. Percutaneous lymphography using particulate fluorocarbon emulsions
GB8916780D0 (en) * 1989-07-21 1989-09-06 Nycomed As Compositions
GB8916782D0 (en) * 1989-07-21 1989-09-06 Nycomed As Compositions
US5393525A (en) * 1989-07-21 1995-02-28 Nycomed Imaging As Contrast medium comprising superparamagnetic or ferromagnetic particles capable of increasing viscosity after administration
US5120527A (en) * 1989-10-19 1992-06-09 King Chuen Peter Li Paramagnetic oil emulsions as mri contrast agents
GB9003821D0 (en) 1990-02-20 1990-04-18 Danbiosyst Uk Diagnostic aid
US5236694A (en) * 1990-02-21 1993-08-17 The Board Of Regents, The University Of Texas System 19f labelled dextrans and antibodies as nmr imaging and spectroscopy agents
US5154914A (en) * 1990-03-12 1992-10-13 Research Corporation Technologies, Inc. Methods of diagnostic image analysis using lipophilic contrast agents
IN172208B (de) 1990-04-02 1993-05-01 Sint Sa
US5358702A (en) * 1990-04-10 1994-10-25 Unger Evan C Methoxylated gel particle contrast media for improved diagnostic imaging
US5368840A (en) * 1990-04-10 1994-11-29 Imarx Pharmaceutical Corp. Natural polymers as contrast media for magnetic resonance imaging
US5205287A (en) * 1990-04-26 1993-04-27 Hoechst Aktiengesellschaft Ultrasonic contrast agents, processes for their preparation and the use thereof as diagnostic and therapeutic agents
AU636481B2 (en) 1990-05-18 1993-04-29 Bracco International B.V. Polymeric gas or air filled microballoons usable as suspensions in liquid carriers for ultrasonic echography
AU650466B2 (en) * 1990-06-01 1994-06-23 Evan C. Unger Contrast media for ultrasonic imaging
US5215680A (en) * 1990-07-10 1993-06-01 Cavitation-Control Technology, Inc. Method for the production of medical-grade lipid-coated microbubbles, paramagnetic labeling of such microbubbles and therapeutic uses of microbubbles
US5122363A (en) * 1990-12-07 1992-06-16 Board Of Regents, The University Of Texas System Zeolite-enclosed transistion and rare earth metal ions as contrast agents for the gastrointestinal tract
US5370901A (en) * 1991-02-15 1994-12-06 Bracco International B.V. Compositions for increasing the image contrast in diagnostic investigations of the digestive tract of patients
US5205290A (en) * 1991-04-05 1993-04-27 Unger Evan C Low density microspheres and their use as contrast agents for computed tomography
US5147631A (en) * 1991-04-30 1992-09-15 Du Pont Merck Pharmaceutical Company Porous inorganic ultrasound contrast agents
US5302372A (en) * 1992-07-27 1994-04-12 National Science Council Method to opacify left ventricle in echocardiography
US5362478A (en) * 1993-03-26 1994-11-08 Vivorx Pharmaceuticals, Inc. Magnetic resonance imaging with fluorocarbons encapsulated in a cross-linked polymeric shell
BR9405798A (pt) * 1993-02-22 1995-12-12 Vivorx Pharmaceuticals Inc Métodos para liberação in vivo de material biológico e composições úteis dos mesmos
US5547882A (en) * 1995-10-11 1996-08-20 Mosel Vitelic Inc. Method for forming retrograde channel profile by phosphorus implantation through polysilicon gate

Also Published As

Publication number Publication date
EP0638318B1 (de) 1999-06-02
EP0638318A3 (de) 1995-11-29
EP0502814B1 (de) 1995-06-21
DE69232709T2 (de) 2003-04-10
US5792445A (en) 1998-08-11
JPH05148161A (ja) 1993-06-15
DE69203004T2 (de) 1995-10-26
DE69229358T2 (de) 2000-03-02
ATE180678T1 (de) 1999-06-15
DE69229358D1 (de) 1999-07-08
EP0638318A2 (de) 1995-02-15
ES2074350T3 (es) 1995-09-01
EP0502814A3 (en) 1992-10-07
DK0502814T3 (da) 1995-08-21
US5688490A (en) 1997-11-18
EP0627632B1 (de) 2002-07-31
US5370901A (en) 1994-12-06
ATE221668T1 (de) 2002-08-15
GR3017002T3 (en) 1995-11-30
ATE124147T1 (de) 1995-07-15
DE69203004D1 (de) 1995-07-27
EP0502814A2 (de) 1992-09-09
US5653959A (en) 1997-08-05
EP0627632A1 (de) 1994-12-07

Similar Documents

Publication Publication Date Title
DE69232709D1 (de) Zusammensetzungen zur Erhöhung des Bildkontrastes bei Untersuchungen des Verdauungstraktes von Patienten
ZA895936B (en) Pharmaceutical compositions comprising selected lactobacillus strains
RU93042100A (ru) Новые 7-(замещенные)-8-(замещенные)-9-[(замещенные глицил) амидо]-6-деметил-6-дезокситетрациклины
CA2034569A1 (en) Oral pharmaceutical forms of pimobendan
EP0491362A3 (en) Use of peptide pairs with extremely high mutual specific affinity in the domain of in-vitro diagnostics
SE9201930D0 (sv) Gastric antibacterial treatment
CA2008078A1 (en) Use of Dimethylpolysiloxane for the Treatment of Disorders of the Gastrointestinal Tract
GR3003750T3 (de)
ATE77383T1 (de) Chirale rhodium-diphosphinkomplexe fuer asymmetrische hydrierungen.
AU1918292A (en) Use of selected oleophilic compounds with increased biological acceptability to improve the oil-wettability of finely divided solids and their use as fluid-loss additives
AU3523589A (en) Novel iodinated non-ionic triiodobenzene compounds and contrast media containing them
DE69313158D1 (de) Kontrastzusammensetzung für M.R.I. des Gastrointestinaltraktes
AU1630288A (en) Substituted compounds, processes for their preparation and uses thereof
ZA822193B (en) 5,6-dihydro-11-alkylene-morphanthridin-6-ones,their preparation,and drugs containing these compounds
ATE20345T1 (de) 5,6-dihydro-11-alkylen-morphantridin-6-one, ihre herstellung und diese enthaltende arzneimittel.
Preobrazhensky et al. Evaluation of humoral and cellular immunity in patients with recurrent gastric ulcer carrying Campylobacter pyloridis.
ATE71513T1 (de) Behaelter fuer die gleichzeitige verabreichung von bariumsulfatsuspension und luft bei der doppelkontrast-roentgen-untersuchung des oberen verdauungstracktes.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition